Literature DB >> 6328337

Renal excretion of an angiotensin I converting enzyme inhibitor (SA-446) in dogs.

Y Abe, T Okahara, K Miura, T Yukimura, T Takada, T Iwatani, T Iso, K Yamamoto.   

Abstract

The renal excretory mechanism of an orally active inhibitor of angiotensin converting enzyme (SA-446) was examined in anesthetized dogs. Parenteral administration of this compound resulted in production of constant levels of about 2 mg/l in the plasma (PSA) and the urine concentration was 726 +/- 200 mg/l, a level significantly higher than that in the plasma. Renal clearance of SA-446 (CSA) was 2.24 +/- 0.34 ml/g X min and was significantly higher than GFR. The clearance ratio (CSA/GFR) of over 1.0 was indicative of a net tubular secretion. Administration of probenecid resulted in a significant rise in PSA and in a significant decrease in urinary excretion but with no change in the plasma protein binding ratio. CSA decreased significantly from 2.24 +/- 0.34 to 0.71 +/- 0.14 ml/g X min. The inhibitory action of SA-446 (0.02 mg/kg, i.v.) on the pressor response to angiotensin I disappeared at about 50 min, this action being maintained for about 2 h in the probenecid pretreated dog. Since probenecid is a competitive inhibitor of organic anion secretory transport, our results show the net tubular secretion of SA-446, via organic anion transport systems. Prolongation of the action of SA-446, as induced by probenecid may be due to the increase of plasma concentration, by the inhibition of tubular secretion.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6328337     DOI: 10.1007/bf00504381

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  11 in total

1.  'Benemid,' p-(di-n-propylsulfamyl)-benzoic acid; its renal affinity and its elimination.

Authors:  K H BEYER; H F RUSSO; E K TILLSON; A K MILLER; W F VERWEY; S R GASS
Journal:  Am J Physiol       Date:  1951-09

2.  Effects of an orally active converting enzyme inhibitor (YS-980) on renal function in dogs.

Authors:  Y Abe; K Miura; M Imanishi; T Yukimura; T Komori; T Okahara; K Yamamoto
Journal:  J Pharmacol Exp Ther       Date:  1980-07       Impact factor: 4.030

3.  Determination of SA-446 in human whole blood and urine by electron capture-gas liquid chromatography.

Authors:  T Iwatani; M Naitoh; H Takashina; S Nagamori; Y Itoh; J Iwao
Journal:  Chem Pharm Bull (Tokyo)       Date:  1982-06       Impact factor: 1.645

4.  Synthesis and antihypertensive activity of N-(mercaptoacyl)-thiazolidinecarboxylic acids.

Authors:  M Oya; T Baba; E Kato; Y Kawashima; T Watanabe
Journal:  Chem Pharm Bull (Tokyo)       Date:  1982-02       Impact factor: 1.645

5.  Disposition of captopril in normal subjects.

Authors:  K J Kripalani; D N McKinstry; S M Singhvi; D A Willard; R A Vukovich; B H Migdalof
Journal:  Clin Pharmacol Ther       Date:  1980-05       Impact factor: 6.875

Review 6.  The pharmacological role of the kidney.

Authors:  D C Brater
Journal:  Drugs       Date:  1980-01       Impact factor: 9.546

7.  Renal handling of captopril: effect of probenecid.

Authors:  S M Sinhvi; K L Duchin; D A Willard; D N McKinstry; B H Migdalof
Journal:  Clin Pharmacol Ther       Date:  1982-08       Impact factor: 6.875

8.  Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents.

Authors:  M A Ondetti; B Rubin; D W Cushman
Journal:  Science       Date:  1977-04-22       Impact factor: 47.728

9.  A new potent inhibitor of converting enzyme: (2R,4R)-2-(2-hydroxyphenyl)-3-(3-mercaptopropionyl)-4-thiazolidinecarboxylic acid(SA446).

Authors:  T Iso; H Yamauchi; H Suda; K Nakata; K Nishimura; J Iwao
Journal:  Jpn J Pharmacol       Date:  1981-12

10.  Inhibitor of angiotensin I converting enzyme: (4R)-3-[(2S)-3-mercapto-2-methylpropanoyl]-4-thiazolidinecarboxylic acid (YS-980).

Authors:  Y Funae; T Komori; D Sasaki; K Yamamoto
Journal:  Biochem Pharmacol       Date:  1980-06-01       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.